“Thank you for your interest in the company. We are a global advisory firm specializing in cross-border deal flow focused in China’s healthcare industry. The firm is the leading platform to facilitate partnerships to fuse Chinese capital, its large and fast-growing market with US/EU healthcare innovation.
With an experienced team of well-connected industry veterans from all over the world and the largest network in China’s healthcare industry, TPP has become the market expert with the top-notch network to execute and support cross-border transactions involving pharmaceuticals, medical devices and diagnostics.”
Tony Chu, Co-Founder / Partner
TPP Management
Tony Chu
Co-Founder / Partner
With over 20 years of cross-border transaction experience in US/EU and Chinese chemical and pharmaceutical industries, Chu is the Founder and Managing Partner of TPP. He also sits as a Board Member for several companies including Eastar Chemical Corp, Pharma Partners Snd Bhd (Malaysia) and PT Inodia (Indonesia).
Mohd Zul Efendi
Partner for Malaysia
Efendi is a Partner at TPP, based in Malaysia. There he boosts 15 years of experience in the ASEAN healthcare industry and recently sat as Senior Manager and Head of Business Development at Pharmaniaga Berhad and BD Director at Biosis Group Berhad.
Ramlan Ibrahim
Partner for Malaysia
Ibrahim is a Partner at TPP, based in Malaysia. With 20 years of experience in pharmaceutical and healthcare in the ASEAN market, he was recently Senior General Manager of Global Sales & Marketing at Pharmaniaga.
Amiram Katzman
Partner
Katzman is a Partner of TPP. With 10+ years of experience in business development, he successfully connects clients with foreign markets and helps leverage their access to quality M&A and investment prospects. He currently serves Prodan Networks as CEO of the company.
Jeremy Kelly
Managing Partner TPP Europe
30+ yrs of experience in Consumer Healthcare Business Development Worldwide. Executive management career with GSK, Pfizer Reckitt Benckiser and L’Oreal. 25+ yrs advisory experience in M&A, Business Development and Strategic Planning with clients including GSK Bayer Pfizer J&J Sanofi Novartis & BI, in N America Latam EU CEE MEA and Apac, across all major therapeutic categories. Over 200 projects completed internationally across all major CHC categories.
Xielong Luo
Board member and Partner TPP China
30+ yrs experience in the Asian (China, Japan) life science industry. Previously, Executive Director of BOAO Asia, International Health Forum, Director of Zhejiang Yangtze Delta Pharmaceutical Research and Development Center, Vice Chairman of Chinese Pharma Enterprises Association and China’s OTC Association in charge of international cooperation especially with Japan and other Asian countries. In his executive roles in China, Mr Luo was the Chairman of Zhejiang Wansheng and Chinese Medical Research Developing Center; President of Beijing Renhe, Hangzhou National Biology Pharma Investment Corporation, Beijing Medical University Yikang Technology Development Corporation and Shenzhen Yizhou Hightech Industry; Vice president of HK Yizhou Corporation
Kevin Xue
Commercial TPP China
20+ years of Chinese and Southeast Asia life sciences industry management experience. In depth knowledge of Chinese pharmaceutical industry and trend for biotech, CHC and TCM products. Previously Director Business Development and Head of Sales and Marketing of Shanghai Union Cell Biological Co., Ltd.
Andrew Deng
Financial Markets TPP China
20+ years of Chinese and international life science industry experience, focusing on capital raise, China IPO, finance strategy and management. Previously founder and CEO of Hong Kong listed company, China Public Procurement Ltd; Ex. Board Director of Haisco Pharma; Mr. Deng was first in China to pioneer the Tibet special channel for listing in China’s A-share stock market by breaking the historic record in listing Haisco in 9.5 months on the Shenzhen Stock Exchange, and maintaining the record in China for 5 years. He promoted Haisco’s market capitalization to 2nd place from 50th; Mr. Deng also was nominated as one of 10 experts to revise the National Accounting Standards by China’s Ministry of finance.
Venture Partners
James Bruno
Venture Partner
Bruno is a Partner at TPP with 40+ years of Senior Executive experience, most notably with Honewell, Viachem, Aeroject and Sipsy. Previously, he was the Former President of the Drug, Chemical & Allied Technologies Association (DCAT) – the largest and oldest pharmaceutical association in the world.
José Luís Fábregas
Venture Partner
Dr. Fabregas is a venture partner at TPP. With decades of pharmaceutical development and licensing in/out experience, he is focused in advisory and consulting projects involving CMC, Pharma and Biotech. Prior to this, Dr. Fabregas was Senior Scientific Director of Pharmaceutical Development at Almirall, S.A.
Amiram Katzman
Venture Partner
Katzman is a Venture Partner of TPP. With 10+ years of experience in business development, he successfully connects clients with foreign markets and helps leverage their access to quality M&A and investment prospects. He currently serves Prodan Networks as CEO of the company.
Shizhong Luo
Venture Partner
Mr. Luo has 20 years of experience managing cross border project, licensing and manufacturing between multnational national companies and Chinese enterprises. He held head of BD Positions at Yabao Pharmaceuticals, Xinhua Pharmceuticals and Board Secretary of JV between Xinhua and Perrigo. He is graduate of Peking University (Master of International Pharmceutical Engineer Management).
Xiao Shu, PhD
Venture Partner
Shu is a Venture Partner for TPP. Currently, Shu sits as the Managing Partner at Guijing Capital and owns 12 years of healthcare investment experience. Previously, he was the Former Portfolio Manager at Kangjing Capital, a healthcare Venture Capital. He graduated from University of California, Berkeley with a PhD degree in Metabolic Biology.
Advisors
Harvey Fine
Advisor
Fine is an Advisor to the cross-border and emerging market private equity group at TPP. His expertise spans strategic partnerships/business development and M&A transactions with emphasis on China and India cross-border deals with the US and Europe. He also serves Fosun Group as the Managing Director in US-Global Investments & Strategies.
Frank Hong
Advisor
In addition to TPP, Mr. Hong is a Managing Director at Legend Capital, focusing on investments in Healthcare. Mr. Hong has rich experience in the pharmaceutical industry and investment in Healthcare. The investment portfolios he has led include: Kawin Technology, Innovent Biologics, PegBio , Baheal Pharmaceutical, Phiskin, Sciwin Biologics, Sinopharm Rfl etc. Prior to Legend Capital, Mr. Hong worked at ShiYu Capital, Nanjing University of Traditional Chinese Medicine, Bayer Healthcare. Mr. Hong holds a Bachelor’s degree from China Pharmaceutical University and a MBA from TongJi University.
Scott Rizzo
Advisor
Scott Rizzo brings over 30 years of leadership experience and operational excellence to Societal™ CDMO as the senior vice president and chief operating officer. Scott joined Societal in 2015 and has been instrumental in developing a client-focused culture at the Georgia-based CDMO. With full profit and loss (P&L) responsibility for the CDMO business, Scott drives strategic initiatives to yield continued business growth while prioritizing employee development and community relations through engagements with the Greater Hall Chamber of Commerce and Georgia Bio. Before joining Societal, Scott held various leadership positions in large and small pharmaceutical businesses and consulting organizations, including Roche Pharmaceuticals, Barrier Therapeutics, J. Knipper, DuPont, and PricewaterhouseCoopers. Scott is a graduate of Pennsylvania State University, where he earned both his Master of Business Administration and Master of Manufacturing Management degrees. He is currently a board member of Georgia Bio and formerly a member of the Rutgers University Graduate Center for Supply Chain Management and the alumni advisory board for Pennsylvania State University.
Lefei Sun
Advisor
Lefei currently serves as Founding Partner of HuaTai Healthcare Investment Fund. With more than 10 years of experience in healthcare analysis and M&A, he possesses strong knowledge in healthcare PE/VC investments in Greater China regions and cross-border deals, and supports global SME healthcare company in China market development.
Alex Xu
Advisor
Alex has over 20 years experience in China as Surgeon and executive management positions including Country Manager of CR Bard. Alex currently is Managing Partner of China Medtech Commercialization Fund 1 (CMC1). Chairman/CEO of Beijing GMT, an oncology focused diagnostic and device company in China.
Pei Zhou
Advisor
Pei is currently Partner of China Medtech Commercialization Fund 1 (CMC 1); Co-head of Pagoda Capital Healthcare. With more than 15 years of research and investment experience in the healthcare industry. Previously, Dr. Zhou served as a Senior Associate of China Everbright Limited Healthcare Investment Fund and has a vast reputation for sourcing, evaluating and the execution of equity investments in Pharmaceutical, medtech and healthcare services sub-sectors.
Strategic Alliances
Note: Partial List